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In patients with metastatic renal cell carcinoma, risk stratification according to the 
Memorial Sloan-Kettering Cancer Center or the International Metastatic Renal Cell 
Carcinoma Database Consortium classification systems is a crucial part of clinical 
assessment and essential for guiding management. New research has now 
demonstrated that disagreement in risk-group classification is common and 
prognostically relevant.  
 
 
Refers to Okita, K. et al. Impact of disagreement between two risk group models on prognosis 
in patients with metastatic renal cell carcinoma. Clin Genitourin. Cancer 
https://dx.doi.org.10.1016/j.clgc.2019.01.006 (2019).  
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In patients with newly diagnosed metastatic renal cell carcinoma (mRCC), risk 
stratification is a crucial part of clinical assessment and essential for guiding 
management. Major clinical trials defining current treatment paradigms have relied on 
the Memorial Sloan-Kettering Cancer Center (MSKCC)1 or the International 
Metastatic Renal Cell Carcinoma Database Consortium (IMDC)2 risk-group 
classifications. Both were established using similar methodology and are fairly 
comparable with regards to variables and risk-group assignment (Table 1). The 
MSKCC classification was developed using data from patients treated with cytokines, 
whereas the IMDC model was established using data from patients treated with 
targeted therapies. The IMDC classification uses markers of systemic inflammatory 
response such as neutrophil and platelet count, but the MSKCC classification 
employs lactate dehydrogenase (LDH) as a marker of cell death.1,2 Current 
guidelines advocate the use of a model but do not recommend one in particular.3 
Even though treatment decisions are often made on the basis of the assigned risk-
group, both classifications have several shortcomings. First and foremost, 
concordance indices (i.e. the discrimination to predict survival) are low,2 and both 
models are prognostic but not predictive. They do not consider metastatic site, tumor 
burden, histological type or molecular markers, which all might improve model 
discrimination. Furthermore, both classifications are mostly blood based and rely on 
dichotomized variables, both of which are problematic. Dichotomization of 
independent variables relies on statistical assumptions that are not reasonable, i.e. 
that the association with the outcome is flat in each group. The cutpoints used in 
laboratories are often derived from percentiling the readings of a healthy cohort, but 
there is no agreement if these cutpoints are valid in patients with mRCC. Finally, 
dichotomization is completely at odds with the concept of making optimal decisions, 
which relies on a function that takes all other predictors into consideration.4 Finally, 
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none of the blood variables currently included in the MSKCC and IMDC system are 
sensitive for RCC or even for cancer, and the classification is dynamic. Indeed, the 
risk group into which the patient is classified can change quickly without intervention 
if blood values are close to the normal range or if performance status is assessed by 
another person. Additionally, cytoreductive nephrectomy has been shown to result in 
normalization of neutrophil and platelet counts in the majority of patients.5 These 
factors can all result in a change in risk-group classification and management 
recommendations.  
Little research has been conducted on the agreement in risk-group classification 
between the MSKCC and IMDC classification systems. Recently, Okita et al.6 studied 
176 patients with synchronous or asynchronous mRCC who received first-line 
sunitinib, sorafenib or axitinib. Although Cohen’s κ coefficient demonstrated good 
agreement between both classification systems in general, disagreement was seen in 
about one-quarter of patients. This involved a change from MSKCC intermediate-risk 
to IMDC-poor-risk disease or vice versa in >80% of reclassified patients, and the 
majority of changes were related to the neutrophil count. Disagreement was 
associated with reduced progression-free survival (HR 1.9, P = 0.025) and overall 
survival (HR=1.75, P = 0.028).6 Thus, disagreement is common, prognostically 
relevant and has the potential to influence management. 
The CARMENA trial7 (NCT00930033) showed that sunitinib alone is not inferior to 
immediate cytoreductive nephrectomy followed by sunitinib in patients with 
synchronous metastatic clear-cell RCC. The CARMENA trial relied on the MSKCC 
classification and stratified disease into intermediate risk and poor risk, which covers 
nearly 100% of patients with synchronous mRCC, as patients with this disease 
cannot be stratified into the favorable-risk group at the time of presentation. Only 
patients whose disease does not require systemic treatment for at least 1 year can 
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be classified into the favorable-risk group, which can only be judged retrospectively. 
On the basis of prospective and retrospective evidence, the European Association of 
Urology Guidelines3 recommend not to perform cytoreductive nephrectomy in 
patients classified as having MSKCC poor-risk disease, not to perform immediate 
cytoreductive nephrectomy in patients classified as having MSKCC intermediate-risk 
disease with an asymptomatic primary tumor who require systemic treatment and to 
perform immediate cytoreductive nephrectomy in patients with good performance 
status and MSKCC favorable- or intermediate-risk disease who do not require 
immediate systemic treatment. Thus, cytoreductive nephrectomy can be offered to a 
minority of patients with MSKCC intermediate-risk disease and the chance of these 
patients having IMDC poor-risk disease is 25-30% according to Okita et al.6 The 
results of CARMENA are not applicable to the IMDC classification owing to the 
differences between the classification systems, but patients with IMDC poor-risk 
disease are unlikely to benefit from surgery.8  
Currently, recommended systemic first-line treatments for mRCC are sunitinib, 
pazopanib, cabozantinib, or nivolumab plus ipilimumab.3 Trials leading to approval of 
these agents differed with regards to inclusion criteria and risk-group classification. 
On the basis of the results of the CheckMate 214 trial9 (NCT02231749), nivolumab 
plus ipilimumab has now become standard fist-line treatment for patients with IMDC-
intermediate or poor-risk disease. The results of this trial are not applicable to 
patients with favorable-risk disease, for which sunitinib or pazopanib remain the 
preferred options. The original sunitinib trial (NCT0008388910) included patients of all 
prognostic groups, but risk group was assigned according to the MSKCC 
classification system. As a progression-free survival benefit of sunitinib was seen in 
all subgroups of patients10, and nivolumab plus ipilimumab was superior to sunitinib 
for IMDC intermediate-risk and poor-risk disease9, disagreement between MSKCC 
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and IMDC has no effect on guideline-recommended first-line treatment. However, 
importantly, nearly 50% of patients with IMDC poor-risk disease could be reclassified 
to the MSKCC intermediate-risk group, whereas 50% would remain in the MSKCC 
poor-risk group according to the results of Okita and colleagues.6 Evidence is 
insufficient to support use of sunitinib in patients with MSKCC poor-risk disease and, 
therefore, it might not be an alternative option for these patients if nivolumab plus 
ipilimumab is not feasible or safe.  
In summary, risk group disagreement between MSKCC and IMDC is common and 
generally associated with poor prognosis, but the guideline-recommended first-line 
treatment remains unaltered in the vast majority of patients. Group disagreement 
could be routinely assessed as prognostic factor in clinical practice and might 
improve discrimination of current models. 
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Table 1. MSKCC and IMDC risk classifications for mRCC 
 
Variable Risk factor  Risk group 
MSKCC   
Time from initial 
diagnosis to systemic 
treatment 
<1 year 0 RF: favorable  
1-2 RF: intermediate  
3-5 RF: poor  
Hemoglobin <lower limit of normal range  
Corrected calcium  >10mg/dl  
Lactate dehydrogenase  >1.5x upper limit of normal range 
Karnofsky Performance 
Status  
<80% 
IMDC   
Time from initial 
diagnosis to systemic 
treatment 
<1 year 0 RF: favorable  
1-2 RF: intermediate  
3-6 RF: poor  
Hemoglobin <lower limit of normal range 
Corrected calcium  >upper limit of normal range 
Neutrophil count >upper limit of normal range 
Platelet count >upper limit of normal range 
Karnofsky Performance 
Status  
<80% 
IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; 
mRCC, metastatic renal cell carcinoma; MSKCC; Memorial Sloan-Kettering 
Cancer Center; RF, risk factor. 
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